Akero Therapeutics financials at a glance

+ Portfolio

The revenue of Akero Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -2.97 Dollars per share in 2023, which was 0.69 higher than 2021. And about -0.114 billion Dollars are reported as free cash flow in the financials of Akero Therapeutics 2023. No dividends were paid to the shareholders of the Akero Therapeutics stock NasdaqGS:AKRO in the financial year 2023.

$0.00M

Revenue

$-2.87

Earnings Per Share

0.00%

Gross Margin %

$-92.52M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-2.87

Gross Margin %

0.00

Free Cash Flow

-92.52

Financials

Year	Year	TTM	2022	2021	2020	2019	2018
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-2.38	$-2.87	$-2.89	$-2.52	$-2.90	$-1.01
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	-0.00%	0	0	0
Sha.	Shares	N/AM	46.97M	35.01M	34.77M	28.61M	0.24M
OCF	Operating Cash Flow	N/A	$-92.52M	$-79.50M	$-70.80M	$-35.63M	$0.00M
FCF	Free Cash Flow	N/A	$-92.52M	$-79.68M	$-70.95M	$-35.63M	$0.00M
FCFS	Free Cash Flow Per Share	$-2.43	$-2.37	$-2.29	$-2.26	$-2.36	$0.00

Akero Therapeutics financials at a glance

Financials

Discover